Cue Biopharma (CUE) Cash from Investing Activities (2017 - 2025)

Cue Biopharma has disclosed Cash from Investing Activities across 9 years of filings, most recently posting $7.0 million for Q4 2025.

• Cash from Investing Activities for Q4 2025 came in at $7.0 million, up 702100.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $75000.0 (up 134.38% YoY), and the FY2025 annual result was $75000.0, up 134.38% from the prior year.
• Cash from Investing Activities came in at $7.0 million for Q4 2025 at Cue Biopharma, up from -$6.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $15.0 million in Q1 2023 to a low of -$29.5 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is -$10000.0 (2024), against an average of $505658.5.
• Peak annual rise in Cash from Investing Activities reached 978177.89% in 2022, while the deepest fall reached 268263.64% in 2022.
• Cue Biopharma's Cash from Investing Activities stood at $511.0 in 2021, then surged by 978177.89% to $5.0 million in 2022, then increased by 0.02% to $5.0 million in 2023, then slumped by 100.02% to -$1000.0 in 2024, then soared by 702100.0% to $7.0 million in 2025.
• The last three Cash from Investing Activities figures came in at $7.0 million (Q4 2025), -$6.8 million (Q3 2025), and -$27000.0 (Q2 2025), per Business Quant data.